Literature DB >> 26215768

Effect of Tadalafil on Myocardial and Endothelial Function and Exercise Performance After Modified Fontan Operation.

Mohammad-Reza Sabri1, Ali Zolfi-Gol2, Alireza Ahmadi1, Shaghayegh Haghjooy-Javanmard1.   

Abstract

Better postoperative management of patients who have undergone single ventricle (SV) Fontan procedure could potentially reduce long-term complications and improve the quality of life for patients. The present study determined the effect of tadalafil on myocardial and endothelial function and exercise performance after modified Fontan operation. Patients who had undergone SV modified Fontan operation were enrolled in this clinical trial. The demographic characteristics of the patients were recorded. Before administration of tadalafil and after the trial, ventricular function (MPI, EF, FS, E/A, VTI), exercise performance, and endothelial function were evaluated for sonographic and biochemical markers (FMD, IMT, ICAM, VCAM, NO) using echocardiography, exercise testing, vascular ultrasonography, and biochemical measurements, respectively. A single dose of tadalafil of 1 mg/kg was administered daily for 6 weeks, and the functional class of the patients before and after tadalafil was determined. A total of 15 patients completed this clinical trial. Tadalafil was shown to have a significant effect on myocardial function, exercise performance, and improvement in NYHA functional class (p < 0.05) of study population. It had no significant effect on the biochemical variables and endothelial function except for IMT (p > 0.05), which decreased significantly after tadalafil administration (p < 0.05). The findings indicate that tadalafil is a safe, well-tolerated agent for the use after modified Fontan operation to improve myocardial function and exercise performance and possibly reduce long-term morbidity and mortality of patients. More conclusive results could be obtained from further study with a larger sample size and long-term follow-up.

Entities:  

Keywords:  Endothelial function; Exercise; Fontan procedure; Single ventricle; Tadalafil

Mesh:

Substances:

Year:  2015        PMID: 26215768     DOI: 10.1007/s00246-015-1238-x

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  28 in total

Review 1.  The failing Fontan: etiology, diagnosis and management.

Authors:  David J Goldberg; Robert E Shaddy; Chitra Ravishankar; Jack Rychik
Journal:  Expert Rev Cardiovasc Ther       Date:  2011-06

2.  Sildenafil exposure and hemodynamic effect after stage II single-ventricle surgery.

Authors:  Kevin D Hill; Robert D Tunks; Piers C A Barker; Daniel K Benjamin; Michael Cohen-Wolkowiez; Gregory A Fleming; Matthew Laughon; Jennifer S Li
Journal:  Pediatr Crit Care Med       Date:  2013-07       Impact factor: 3.624

Review 3.  Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors.

Authors:  Graham Jackson
Journal:  Am J Cardiol       Date:  2005-12-05       Impact factor: 2.778

4.  Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension.

Authors:  Flora Affuso; Emiliano Antonio Palmieri; Pasquale Di Conza; Vincenzo Guardasole; Serafino Fazio
Journal:  Int J Cardiol       Date:  2005-11-02       Impact factor: 4.164

Review 5.  Challenges of management and therapy in patients with a functionally single ventricle after Fontan operation.

Authors:  Olga Trojnarska; Aleksandra Ciepłucha
Journal:  Cardiol J       Date:  2011       Impact factor: 2.737

6.  Impaired flow-mediated vasodilation, carotid artery intima-media thickening, and elevated endothelial plasma markers in obese children: the impact of cardiovascular risk factors.

Authors:  Andreas Alexander Meyer; Günther Kundt; Michael Steiner; Peter Schuff-Werner; Wolfgang Kienast
Journal:  Pediatrics       Date:  2006-05       Impact factor: 7.124

7.  [Decrease ApoB/ApoA-1 ratio and cardiovascular risk improvement: a tadalafil pleiotropic effect? Preliminary study on healthy volunteers].

Authors:  T Roumeguère; K Zouaoui Boudjeltia; C Hauzeur; A Ramal; C Schulman; M Vanhaeverbeek; J Ducobu; E Wespes
Journal:  Prog Urol       Date:  2008-11-13       Impact factor: 0.915

8.  Ventricular afterload and ventricular work in fontan circulation: comparison with normal two-ventricle circulation and single-ventricle circulation with blalock-taussig shunts.

Authors:  Hideaki Senzaki; Satoshi Masutani; Jun Kobayashi; Toshiki Kobayashi; Nozomu Sasaki; Haruhiko Asano; Shunei Kyo; Yuji Yokote; Akira Ishizawa
Journal:  Circulation       Date:  2002-06-18       Impact factor: 29.690

9.  Tadalafil therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Bruce H Brundage; Hossein A Ghofrani; Ronald J Oudiz; Gerald Simonneau; Zeenat Safdar; Shelley Shapiro; R James White; Melanie Chan; Anthony Beardsworth; Lyn Frumkin; Robyn J Barst
Journal:  Circulation       Date:  2009-05-26       Impact factor: 29.690

10.  Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials.

Authors:  Elisa Giannetta; Tiziana Feola; Daniele Gianfrilli; Riccardo Pofi; Valentina Dall'Armi; Roberto Badagliacca; Federica Barbagallo; Andrea Lenzi; Andrea M Isidori
Journal:  BMC Med       Date:  2014-10-20       Impact factor: 8.775

View more
  3 in total

Review 1.  Management of Pulmonary Arterial Hypertension in the Pediatric Patient.

Authors:  Jordan E Ezekian; Kevin D Hill
Journal:  Curr Cardiol Rep       Date:  2019-11-28       Impact factor: 2.931

2.  Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliation.

Authors:  David J Goldberg; Victor Zak; Bryan H Goldstein; Shan Chen; Michelle S Hamstra; Elizabeth A Radojewski; Eileen Maunsell; Seema Mital; Shaji C Menon; Kurt R Schumacher; R Mark Payne; Mario Stylianou; Jonathan R Kaltman; Tina M deVries; James L Yeager; Stephen M Paridon
Journal:  Am Heart J       Date:  2017-03-06       Impact factor: 4.749

3.  Induction of aggressive arterial and venous dilation therapy in addition to pulmonary dilation therapy (super-Fontan strategy) improves Fontan circulation both at rest and during treadmill exercise.

Authors:  Shoichi Ishikawa; Shun Matsumura; Akiko Yana; Clara Kurishima; Yoichi Iwamoto; Hirotaka Ishido; Satoshi Masutani; Ryo Nakagawa; Hideaki Senzaki
Journal:  JTCVS Open       Date:  2022-07-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.